What is the share price of Emcure Pharmaceuticals Ltd (EMCURE) today?
The share price of EMCURE as on 5th December 2025 is ₹1395.40. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Emcure Pharmaceuticals Ltd (EMCURE) share?
The past returns of Emcure Pharmaceuticals Ltd (EMCURE) share are- Past 1 week: -1.49%
- Past 1 month: 5.37%
- Past 3 months: 2.39%
- Past 6 months: 5.21%
- Past 1 year: 2.25%
- Past 3 years: N/A%
- Past 5 years: 3.26%
What are the peers or stocks similar to Emcure Pharmaceuticals Ltd (EMCURE)?
The peers or stocks similar to Emcure Pharmaceuticals Ltd (EMCURE) include:What is the dividend yield % of Emcure Pharmaceuticals Ltd (EMCURE) share?
The current dividend yield of Emcure Pharmaceuticals Ltd (EMCURE) is 0.21.What is the market cap of Emcure Pharmaceuticals Ltd (EMCURE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Emcure Pharmaceuticals Ltd (EMCURE) is ₹26605.43 Cr as of 5th December 2025.What is the 52 week high and low of Emcure Pharmaceuticals Ltd (EMCURE) share?
The 52-week high of Emcure Pharmaceuticals Ltd (EMCURE) is ₹1519.90 and the 52-week low is ₹889.What is the PE and PB ratio of Emcure Pharmaceuticals Ltd (EMCURE) stock?
The P/E (price-to-earnings) ratio of Emcure Pharmaceuticals Ltd (EMCURE) is 39.05. The P/B (price-to-book) ratio is 5.73.Which sector does Emcure Pharmaceuticals Ltd (EMCURE) belong to?
Emcure Pharmaceuticals Ltd (EMCURE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Emcure Pharmaceuticals Ltd (EMCURE) shares?
You can directly buy Emcure Pharmaceuticals Ltd (EMCURE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Emcure Pharmaceuticals Ltd
EMCURE Share Price
1,395.400.58% (-8.10)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
EMCURE Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
EMCURE Performance & Key Metrics
EMCURE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 33.55 | 5.73 | 0.21% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
83%
Analysts have suggested that investors can buy this stock
from 6 analysts
Price Upside
Earnings Growth
Rev. Growth
EMCURE Company Profile
Emcure Pharmaceuticals is engaged in developing, manufacturing and marketing a range of pharmaceutical products across several therapeutic areas.
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
EMCURE Sentiment Analysis
EMCURE Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
EMCURE Stock Summary · August 2025
In Q1 FY26, the company achieved a remarkable 15.7% revenue growth and a 41% increase in profit after tax, driven by strong performance in key therapy areas and a robust international business, particularly in emerging markets. While challenges such as regulatory hurdles and competition persist, management remains optimistic about future growth, bolstered by a healthy product pipeline and strategic investments in innovation. The focus on operational efficiency has led to improved gross margins and EBITDA, with plans to enhance margins further over the next few years. Additionally, the company is committed to addressing unmet medical needs, particularly in women's health and diabetes, while maintaining a strong cash position to support its growth initiatives.
EMCURE Stock Growth Drivers
EMCURE Stock Growth Drivers
7Strong Financial Performance
Emcure Pharmaceuticals reported a robust financial performance for Q1 FY '26, achieving a revenue growth
Successful Product Launches and Portfolio Expansion
The company successfully launched two new products targeting women's health, focusing on PCOS and menopause,
EMCURE Stock Challenges
EMCURE Stock Challenges
0
Hmm, looks like there are nochallenges
EMCURE Forecast
EMCURE Forecasts
Price
Revenue
Earnings
EMCURE Share Price Forecast
EMCURE Share Price Forecast
2025
Current
₹1,403.50
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹1,403.50
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
EMCURE Company Revenue Forecast
EMCURE Company Revenue Forecast
2025
Current
₹7.97
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹7.97
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
EMCURE Stock EPS (Earnings Per Share) Forecast
EMCURE Stock EPS (Earnings Per Share) Forecast
2025
Current
₹36.77
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹36.77
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
EMCURE
EMCURE
Income
Balance Sheet
Cash Flow
Annual Normal View
EMCURE Income Statement
EMCURE Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,274.01 | 4,911.74 | 5,130.86 | 5,067.35 | 5,918.86 | 6,031.72 | 6,715.24 | 7,968.79 | 8,457.27 | |||||||||
Raw Materials | 1,414.88 | 1,890.86 | 2,027.58 | 2,188.68 | 2,378.55 | 2,193.84 | 2,665.61 | 3,410.14 | 6,806.71 | |||||||||
| Power & Fuel Cost | 83.14 | 94.47 | 100.81 | 94.85 | 97.28 | 108.58 | 120.04 | 138.00 | ||||||||||
| Employee Cost | 887.46 | 1,010.33 | 1,105.62 | 902.81 | 1,011.82 | 1,117.33 | 1,292.08 | 1,446.29 | ||||||||||
| Selling & Administrative Expenses | 651.74 | 684.16 | 809.58 | 403.93 | 716.19 | 840.84 | 998.47 | 1,077.84 | ||||||||||
| Operating & Other expenses | 542.55 | 411.47 | 404.50 | 420.10 | 321.63 | 550.19 | 362.26 | 365.26 | ||||||||||
EBITDA | 694.24 | 820.45 | 682.77 | 1,056.98 | 1,393.39 | 1,220.94 | 1,276.78 | 1,531.26 | 1,650.56 | |||||||||
| Depreciation/Amortization | 228.05 | 267.17 | 320.83 | 249.99 | 244.86 | 260.12 | 312.41 | 384.13 | 397.75 | |||||||||
| PBIT | 466.19 | 553.28 | 361.94 | 806.99 | 1,148.53 | 960.82 | 964.37 | 1,147.13 | 1,252.81 | |||||||||
| Interest & Other Items | 175.73 | 222.66 | 256.60 | 154.94 | 175.98 | 213.61 | 237.15 | 175.78 | 130.11 | |||||||||
| PBT | 290.46 | 330.62 | 105.34 | 652.05 | 972.55 | 747.21 | 727.22 | 971.35 | 1,122.70 | |||||||||
| Taxes & Other Items | 115.37 | 135.55 | 21.73 | 233.44 | 310.35 | 215.20 | 229.04 | 290.02 | 329.62 | |||||||||
| Net Income | 175.09 | 195.07 | 83.61 | 418.61 | 662.20 | 532.01 | 498.18 | 681.33 | 793.08 | |||||||||
| EPS | 9.68 | 10.79 | 4.62 | 23.15 | 36.62 | 29.42 | 27.52 | 36.77 | 41.85 | |||||||||
| DPS | 3.50 | 3.50 | 2.50 | 1.00 | 3.00 | 2.00 | 2.00 | 3.00 | 3.00 | |||||||||
| Payout ratio | 0.36 | 0.32 | 0.54 | 0.04 | 0.08 | 0.07 | 0.07 | 0.08 | 0.07 |
EMCURE Company Updates
EMCURE Stock Peers
EMCURE Past Performance & Peer Comparison
EMCURE Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Emcure Pharmaceuticals Ltd | 39.05 | 5.73 | 0.21% |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
EMCURE Stock Price Comparison
Compare EMCURE with any stock or ETFCompare EMCURE with any stock or ETF
EMCURE
EMCURE Holdings
EMCURE Shareholdings
EMCURE Promoter Holdings Trend
EMCURE Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
EMCURE Institutional Holdings Trend
EMCURE Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
EMCURE Shareholding Pattern
EMCURE Shareholding Pattern
EMCURE Shareholding History
EMCURE Shareholding History
Foreign Institutions
Mutual Funds Invested in EMCURE
Mutual Funds Invested in EMCURE
No mutual funds holding trends are available
Top 5 Mutual Funds holding Emcure Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5274% | Percentage of the fund’s portfolio invested in the stock 0.89% | Change in the portfolio weight of the stock over the last 3 months -0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 57/71 (-13) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4996% | Percentage of the fund’s portfolio invested in the stock 0.27% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 104/142 (-46) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2483% | Percentage of the fund’s portfolio invested in the stock 0.55% | Change in the portfolio weight of the stock over the last 3 months 0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 63/92 (+6) |
Compare 3-month MF holding change on Screener
smallcases containing EMCURE stock
smallcases containing EMCURE stock
Looks like this stock is not in any smallcase yet.
EMCURE Events
EMCURE Events
EMCURE Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
EMCURE has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.21%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.14 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
EMCURE Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
EMCURE has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.21%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.14 every year
EMCURE Upcoming Dividends
EMCURE Upcoming Dividends
No upcoming dividends are available
EMCURE Past Dividends
EMCURE Past Dividends
Cash Dividend
Ex DateEx DateAug 14, 2025
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Aug 14, 2025
EMCURE Stock News & Opinions
EMCURE Stock News & Opinions
Articles & Videos
Earnings
Emcure Pharmaceuticals consolidated net profit rises 25.13% in the September 2025 quarter
Net profit of Emcure Pharmaceuticals rose 25.13% to Rs 243.46 crore in the quarter ended September 2025 as against Rs 194.57 crore during the previous quarter ended September 2024. Sales rose 13.38% to Rs 2269.82 crore in the quarter ended September 2025 as against Rs 2001.98 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales2269.822001.98 13 OPM %20.9519.03 - PBDT446.06370.31 20 PBT341.42273.41 25 NP243.46194.57 25 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Novo Nordisk India partners with Emcure launch Poviztra' in India
Novo Nordisk India and Emcure Pharma today announced a strategic partnership to launch Poviztra', semaglutide injection 2.4 mg, in India. The collaboration will strengthen the distribution and marketing of semaglutide for weight loss, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India. Wegovy' (semaglutide injection 2.4 mg) was launched in India in June 2025. It is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity.1 In clinical trials, 1 in 3 participants on Wegovy' experienced weight loss of over 20%.2 Poviztra' is a second brand of Wegovy'. This partnership is part of Novo Nordisk India's efforts to ensure its innovative treatments reach a greater number of patients in India, broadening access to high-quality, safe, and effective weight management medication. As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviz tra', semaglutide injection 2.4 mg, in India. Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Emcure Pharmaceuticals to hold board meeting
Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Emcure Pharmaceuticals' Kadu unit clears USFDA inspection
Emcure Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) had conducted surveillance inspection of Company's manufacturing facility located at Survey No. 485 (New), 160/P1 (Old), Kadu, Taluka - Lakhtar, District- Surendranagar, Gujarat - 382775, from 06 October 2025 to 10 October 2025. The inspection is concluded without any observation. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Emcure Pharmaceuticals consolidated net profit rises 43.64% in the June 2025 quarter
Net profit of Emcure Pharmaceuticals rose 43.64% to Rs 206.95 crore in the quarter ended June 2025 as against Rs 144.08 crore during the previous quarter ended June 2024. Sales rose 15.72% to Rs 2100.54 crore in the quarter ended June 2025 as against Rs 1815.14 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales2100.541815.14 16 OPM %19.8418.53 - PBDT393.71301.00 31 PBT294.26207.41 42 NP206.95144.08 44 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Emcure Pharmaceuticals to hold AGM
Emcure Pharmaceuticals announced that the 44th Annual General Meeting(AGM) of the company will be held on 28 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Emcure Pharmaceuticals to discuss results
Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Emcure Pharmaceuticals signs exclusive agreement with Sanofi India
Emcure Pharmaceuticals (Emcure) and Sanofi India (SIL) today entered into an exclusive distribution and promotion agreement for SIL's oral anti-diabetic (OAD) products in India, effective immediately. Emcure will exclusively distribute and promote the Company's OAD range of products that include well-established brands like Amaryl' and Cetapin'. While SIL will continue to own and manufacture these brands across Sanofi's plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all of India. There will be no people transition from SIL to Emcure in this arrangement.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Emcure Pharmaceuticals appoints President - India Business
Emcure Pharmaceuticals has appointed R.S. Vasan as President - India Business and Senior Management Personnel (SMP) of the Company w.e.f. 14 July 2025, as per Regulation 16(1)(d) of SEBI Listing Regulations. Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Emcure Pharma gains after Sanand facility gets zero observations from USFDA
The inspection conducted from 30 June 2025 to 08 July 2025 and concluded without issuance of Form 483, indicating zero observations. Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. The company's consolidated net profit jumped 64.1% to Rs 188.96 crore on 19.5% increase in net sales to Rs 2,116.25 crore in Q4 FY25 over Q4 FY24.Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 9.2%, vs industry avg of 10.03%
Over the last 5 years, market share decreased from 2.04% to 1.89%
Over the last 5 years, net income has grown at a yearly rate of 52.13%, vs industry avg of 20.02%